Immunotherapy has offered a second line of treatment; however, only approximately 20% of patients respond, and molecular subtyping of tumors indicates there may be significant overlap in those patients that respond to cisplatin and those patients that respond to immunotherapy.
← all excerpts
Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer.
1
—
—